Novo Nordisk has secured European Union approval for its oral obesity drug, amycretin. The European Medicines Agency, known as EMA, is scheduled to formally announce the decision on April 26. This approval is a major step forward for the company. It will generate global search interest in the Danish pharmaceutical sector.
Phase 3 clinical trials showed that patients achieved an average weight loss of 15 percent. The pill will be branded as Obecra. It targets two receptors in the body. These are the GLP-1 receptor and the amylin receptor. Novo Nordisk submitted the marketing authorization application to the EMA in October 2025. The EMA's Committee for Medicinal Products for Human Use has already recommended approval of the drug. This committee is responsible for evaluating medicines before final approval.
Novo Nordisk expects to launch Obecra commercially in the third quarter of 2026. The company has set a monthly price of 4,500 Danish kroner for the treatment. This oral formulation offers patients an alternative to injectable obesity medications. The approval is a key moment for Denmark's pharmaceutical industry. It highlights the country's role in developing new treatments for chronic conditions.